Form 4: Oncology Institute Director Acquires 56,000 Shares of Common Stock

Mohit Kaushal, a director at Oncology Institute, acquired 56,000 shares of common stock on November 22, 2024, as part of a restricted stock unit grant.

Summary

• On November 22, 2024, Mohit Kaushal, a director at Oncology Institute, Inc., acquired 56,000 shares of common stock.
• These shares were obtained through a grant of restricted stock units.
• The restricted stock units will vest in full on the date of TOI, Inc.'s 2025 annual shareholder meeting.
• Vesting is contingent upon Mr. Kaushal's continued service with the company through the vesting date.
• Following this transaction, Mr. Kaushal beneficially owns a total of 177,253 shares of common stock.

Sentiment

Score: 7

Explanation: The document reflects a standard transaction of stock grants to a director, which is generally viewed positively as it aligns interests. There are no negative implications.

Positives

• The acquisition of shares by a director demonstrates confidence in the company's future prospects.
• The vesting schedule aligns the director's interests with the long-term success of the company.

Future Outlook

The restricted stock units will vest at the 2025 annual shareholder meeting, subject to continued service.

Industry Context

This type of stock grant is a common practice in publicly traded companies to incentivize and align the interests of directors with the company's performance.

Comparison to Industry Standards

• Stock grants to directors are a standard practice across the industry, often used as part of compensation packages.
• The vesting schedule tied to the annual shareholder meeting is also a common approach to ensure long-term commitment.
• Similar grants can be seen at companies like Amgen and Gilead Sciences, where directors receive equity as part of their compensation.

Stakeholder Impact

• The stock acquisition by a director may be viewed positively by shareholders, indicating confidence in the company's future.

Next Steps

• The restricted stock units will vest at the 2025 annual shareholder meeting, contingent on continued service.

Key Dates

Keywords

Oncology Institute, Mohit Kaushal, stock acquisition, restricted stock units, director, shareholder meeting, vesting